<sub id="h9hdp"></sub>
      <span id="h9hdp"></span>
        <sub id="h9hdp"></sub>
        <sub id="h9hdp"></sub>

        <address id="h9hdp"></address>

          <thead id="h9hdp"></thead>

            Investor due diligence of a development-stage microbiome company

            Due Diligence Challenge: An investor was considering re-investing into a development-stage microbiome company that had experienced certain issues that delayed timelines and changed the risk profile....
            Learn More

            Investor Due Diligence: Pharma Business Development Case Studies

            Alacrita frequently works on behalf of investors to conduct due diligence on prospective transactions. The two case studies below offer a snapshot of the typical expertise we provide in this area. To...
            Learn More

            Virtual Stewardship of a Targeted Cancer Therapy to an IND Submission

            An early-stage biotech company developing a targeted cancer therapy engaged Alacrita to provide expertise to help them navigate an upcoming IND submission. An Alacrita partner and medical oncologist...
            Learn More

            Pharmaceutical Licensing: Negotiation Support

            Alacrita provides support to organizations seeking pharmaceutical licensing opportunities, both in- and out-licensing, as well as negotiation support. Our approach is flexible and can be tailored...
            Learn More

            Due diligence: biologic technologies & phase III probability of success of CNS asset

            Case Study 1, Challenge: A mid-size pharmaceutical company seeking opportunities to diversify within its core therapeutic area by partnering in products based on biologic technologies retained...
            Learn More

            Due diligence: plasma protein manufacturer; Phase III gene therapy asset

            Case Study 1, Challenge: A private equity investor was considering a transaction in a company supplying therapeutic proteins derived from biological sources for the treatment of numerous diseases in...
            Learn More

            Developing an independent market report for a cannabinoid company seeking a dual-listing

            Challenge: A company developing a portfolio of therapeutic cannabinoids for neurological conditions was seeking a stock exchange listing and asked Alacrita to develop documentation supporting its...
            Learn More

            Roadmap for commercial data infrastructure build to support rare disease drug launch

            Challenge: Our client was a clinical-stage biotech in the process of early stage planning for the launch of its first drug, a small molecule treatment for a rare endocrine disorder. However, the...
            Learn More

            University life sciences IP and project portfolio review

            Challenge: Alacrita developed techno-commercial development plans for selected top priority projects. The client, King's Commercialisation Institute, convened an expert panel which then selected...
            Learn More

            Commercial development plan for a mesenchymal stem cell therapy in acute GvHD

            Challenge Our client was a leading UK Research Institute requiring assistance in assigning internal commercialization funding to the most promising research groups within the university. Alacrita was...
            Learn More

            Cell and gene therapy manufacturing facility planning

            Challenge A new GMP facility for the production of investigational cell and gene therapies needed regulatory, market and technical advice before committing to a capacity expansion.
            Learn More

            Due diligence on a new medical imaging technology

            Challenge: A well-capitalized Swiss pharma company needed a clinical and commercial reality check for a new imaging technology being developed that was under consideration for acquisition.
            Learn More
            中文无码人妻影音先锋